Cite

HARVARD Citation

    Moore, A. et al. (n.d.). OC-097 The novel gastrin/CCK2 receptor antagonist YF476 induces clinical responses and is well tolerated in patients with type I gastric neuroendocrine tumours. Gut. pp. A42-A43. [Online]. 
  
Back to record